CLINICAL INNOVATION ApS: Financial statements 2018
CVR: 29924880
Source: annual report 2018, Danish Business Authority
01/10/2017 – 30/09/2018
CLINICAL INNOVATION ApS (CVR 29924880) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK 3,985,000 and a net result of DKK 417,000 compared with DKK 243,000 the year before. That is an increase of 7.1% compared with the year before. Equity in the 2018 report amounted to DKK 3,230,000. The solvency ratio was 43.5%. The company had 7 employees in the financial year.
- Gross Profit
- DKK 3,985,000
- Profit/Loss
- DKK 417,000
- Equity
- DKK 3,230,000
- Total Assets
- DKK 7,432,000
- Employees
- 7
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2018 | - | 4 mio. | 417 t. | 3.2 mio. | 7 |
| 2017 | - | 3.7 mio. | 243 t. | 3 mio. | 7000 |
| 2016 | - | 3.9 mio. | 754 t. | 2.9 mio. | 6000 |
| 2015 | - | 3.2 mio. | 272 t. | 3.1 mio. | - |
| 2014 | - | 2.8 mio. | 483 t. | 2.9 mio. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2018
As of August 8, 2018, Magnus Oliver Lorentzen Dinesen has joined the board of directors of CLINICAL INNOVATION ApS.
CLINICAL INNOVATION ApS has published its annual report for 2017. Gross profit came to DKK 3,721,000, and the net result was DKK 243,000.
About CLINICAL INNOVATION ApS
CLINICAL INNOVATION ApS is a Danish company of the type Anpartsselskab based in Holbæk, founded in 2006. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Claus Michael Dinesen. The board consists of Ole Hedemann (chair), Claus Michael Dinesen, Magnus Oliver Lorentzen Dinesen and Marc Phillip Gall Schultz Lorentzen. The company is owned by PIA & CLAUS DINESEN HOLDING ApS. The company has 5 employees (2026). In 2025, the company reported a gross profit of DKK 2,775,826 and a net result of DKK 413,835 compared with DKK 95,746 the year before. Equity in the 2025 report amounted to DKK 3,821,950.